2025
Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses
Lakshmipathi J, Santha S, Li M, Qian Y, Roy S, Luheshi N, Politi K, Bosenberg M, Eyles J, Muthusamy V. Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses. Cancer Immunology, Immunotherapy 2025, 74: 250. PMID: 40560386, PMCID: PMC12198101, DOI: 10.1007/s00262-025-04105-0.Peer-Reviewed Original ResearchThis study investigates intratumoral IL12 mRNA therapy, showing it effectively reactivates immune responses in checkpoint inhibitor-resistant tumors, leading to significant complete responses, potentially benefiting cancer patients with resistant tumors.
2024
Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.
Wrangle J, Redman M, Husain H, Reckamp K, Stinchcombe T, Edelman M, Leal T, Faller B, Minichiello K, Borghaei H, Kelly K, Herbst R, Gray J. Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy. Journal Of Clinical Oncology 2024, 42: 2619-2619. DOI: 10.1200/jco.2024.42.16_suppl.2619.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerProgression-free survivalPhase II/III studiesN-803Overall survivalIL-15Resistance cohortRecurrent non-small cell lung cancerTreated advanced non-small cell lung cancerLung cancerTreated with anti-PD-1Anti-PD-L1 therapyIL-15 receptor alphaAnti-PD-1Anti-PD-L1Performance of immunotherapiesAnti-PD-(L)1Cell lung cancerCancer related deathGamma-chain familyClinical unmet needStandard of careALT-803Secondary endpointsMinimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy
Niu L, Miao Y, Cao Z, Wei T, Zhu J, Li M, Bai B, Chen L, Liu N, Pan F, Zhu J, Wang C, Yang Y, Chen Q. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy. ACS Nano 2024, 18: 3349-3361. PMID: 38230639, DOI: 10.1021/acsnano.3c10174.Peer-Reviewed Original ResearchConceptsTumor-specific immune responsesBone marrow-derived dendritic cellsCancer immunotherapyDendritic cellsCancer vaccinesActivate tumor-specific immune responsesCell death protein ligand 1Mouse bone marrow-derived dendritic cellsImmune responseMarrow-derived dendritic cellsAnti-PD-L1Codelivery of antigenEffective cancer vaccinesPre-existing tumorsActivated dendritic cellsAntigen Cross-PresentationDC maturationCross-PresentationTumor modelProphylactic efficacyNanovaccineImmune effectsImmunotherapyPeptide antigensCancer
2023
A coordinative dendrimer-based nanovaccine for cancer treatment
Cao Z, Ren L, Niu L, Zhao R, Liu N, Zhuang Q, Pan F, Liu Z, Cheng Y, Yang Y, Chen Q. A coordinative dendrimer-based nanovaccine for cancer treatment. Matter 2023, 6: 3574-3597. DOI: 10.1016/j.matt.2023.08.001.Peer-Reviewed Original ResearchCancer vaccinesCancer immunotherapyDendritic cellsField of cancer immunotherapyTumor-specific immune responsesEffective cancer immunotherapyAnti-PD-L1Efficient antigen cross-presentationAntigen Cross-PresentationCGAS-STING pathwayCross-PresentationImmune responseCancer cellsTherapeutic effectCancer treatmentCancerCGAS-STINGImmunotherapyVaccinePeptide carrierCellsNanovaccineNeoantigensPeptidePatients
2019
ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM)
Kurz S, Silverman J, Hochman T, Nayak L, Arrillaga-Romany I, Lee E, Patel A, Delara M, Hsu F, Imtiaz T, Magnelli L, Taylor J, Cloughesy T, Sulman E, Golfinos J, Zagzag D, Snuderl M, Goldberg J, S A. ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi9-vi10. PMCID: PMC6847193, DOI: 10.1093/neuonc/noz175.036.Peer-Reviewed Original ResearchIDH-mutant glioblastomasHypofractionated radiationFollow-upMedian follow-up timeCohort of adult patientsEfficacy of avelumabSafety lead-inAnti-PD-L1Dose-limiting toxicityTime of progressionIDH-mutant gliomasIncreased cerebral edemaMedian OSMedian PFSWorsened hemiparesisPhase IIOpen-labelSlow accrualTransaminase elevationAvelumabDiscontinued treatmentSingle-armMulticenter studyTreatment regimenAdult patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply